Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and anlotinib with hepatic arterial infusion versus intravenous chemotherapy for first-line advanced biliary tract cancer
ChiCTR2500102333Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- May 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adebrelimab and anlotinib in biliary cancer (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Objective response rate. Started May 2025; status: recruiting.
02
Drugs
adebrelimabanlotinib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2500102333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102333.